Want to see MKKGY full AI Analyst Report?
Merck KGaA Sponsored ADR (MKKGY) AI Stock Analysis
Merck KGaA Sponsored ADR
(Other OTC:MKKGY)
Strong financial foundation and upgraded earnings guidance are the primary drivers, tempered by short-term technical weakness and fair but not compelling valuation.
Merck KGaA Sponsored ADR (MKKGY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $73.22B
- Dividend Yield
- 1.52%
- Average Volume (3M)
- 74.17K
- Price to Earnings (P/E)
- 27.8
- Beta (1Y)
- 0.54
- Revenue Growth
- 6.81%
- EPS Growth
- -11.14%
- Country
- US
- Employees
- 62,461
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Merck KGaA Sponsored ADR Business Overview & Revenue Model
Company Description
Merck KGaA is a leading German science and technology enterprise. Its business operations are strategically organized into three core divisions: Life Science, Healthcare, and Electronics. The Life Science segment provides an extensive portfolio of to...
How the Company Makes Money
Merck KGaA makes money primarily by selling products and services across three business areas. (1) Life Science: The company generates revenue from selling laboratory and production materials, equipment, and services to academic researchers, biotech...
Merck KGaA Sponsored ADR Earnings Call Summary
The call conveyed a broadly positive tone: the company delivered accelerating organic growth, strong margin expansion, notable outperformance in Life Science (Process Solutions) and Electronics (Semiconductor Solutions), upgraded full-year guidance, and announced a strategically accretive Bio‑Techne acquisition. These positives are moderated by clear near-term challenges in Healthcare (notably MAVENCLAD and Specialty Care), dependency on temporary Process Solutions tailwinds that may normalize and possibly create 2027 headwinds, some one-off project contributions in Electronics, and increased leverage from recent and pending transactions. On balance, operational momentum and upgraded guidance outweigh the listed risks in the near term.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Merck raised its 2026 guidance: group organic net‑sales growth is now expected at +1% to +3% (vs 0%–3% prior), with FX headwinds eased to −2% to 0% (previously −3% to −1%), implying group net sales of about EUR 21.0–21.8bn (midpoint equals prior top end of EUR 20.4–21.4bn); EBITDA pre is lifted to EUR 5.9–6.3bn (vs EUR 5.7–6.1bn) with organic EBITDA‑pre development of 0%–3% (vs −2%–+2%), and EPS pre is guided to EUR 7.90–8.60 (vs EUR 7.50–8.20, ~+5%). By division: Life Science organic sales now +5%–7% (lower bound raised from 4%) with a potential tariff‑refund headwind of ~EUR 40m, Life Science EBITDA‑pre organic +5%–8% (EBITDA‑pre ~EUR 2.6–2.8bn); Healthcare organic sales −4% to −2% (improved from −6% to −3%) with Healthcare EBITDA‑pre ~EUR 2.8–3.0bn and the OGSIVEO/GOMEKLI portfolio effect limited to H1 at +2.4% (EUR 207m, recognized as organic from July 1); Electronics organic sales +6%–9% (vs 3%–7% prior) with a Surface Solutions divestment headwind of −EUR 245m and Electronics EBITDA‑pre around EUR 1.0bn (organic EBITDA‑pre growth range moved to 25%–29% from 21%–27%).
Merck KGaA Sponsored ADR Financial Statement Overview
Summary
Resilient cash flows and conservative balance sheet provide stability, offsetting moderate income statement performance with some net margin pressure.
Income Statement
68PositiveBalance Sheet
81Very PositiveCash Flow
86Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.18B | 20.27B | 21.16B | 20.99B | 22.23B | 19.69B |
| Gross Profit | 12.43B | 11.42B | 12.48B | 12.39B | 13.71B | 12.34B |
| EBITDA | 6.61B | 5.71B | 5.96B | 5.57B | 6.29B | 5.93B |
| Net Income | 2.38B | 2.51B | 2.78B | 2.82B | 3.33B | 3.06B |
Balance Sheet | ||||||
| Total Assets | 52.67B | 52.08B | 51.57B | 48.49B | 48.53B | 45.36B |
| Cash, Cash Equivalents and Short-Term Investments | 1.95B | 2.92B | 2.71B | 2.41B | 1.64B | 1.62B |
| Total Debt | 12.30B | 11.96B | 10.27B | 9.86B | 10.40B | 10.77B |
| Total Liabilities | 22.39B | 23.43B | 21.58B | 21.74B | 22.52B | 23.95B |
| Stockholders Equity | 30.16B | 28.58B | 29.91B | 26.68B | 25.93B | 21.34B |
Cash Flow | ||||||
| Free Cash Flow | 2.53B | 2.26B | 2.40B | 1.76B | 2.45B | 3.19B |
| Operating Cash Flow | 4.21B | 3.78B | 4.59B | 3.78B | 4.26B | 4.62B |
| Investing Cash Flow | -5.07B | -4.09B | -3.05B | -1.89B | -2.74B | -1.58B |
| Financing Cash Flow | 1.64B | 603.21M | -985.00M | -1.73B | -1.55B | -2.50B |
Merck KGaA Sponsored ADR Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MKKGY, the sentiment is Positive. The current price of 33.78 is above the 20-day moving average (MA) of 31.94, above the 50-day MA of 31.51, and above the 200-day MA of 29.70, indicating a bullish trend. The MACD of 0.53 indicates Negative momentum. The RSI at 65.42 is Neutral, neither overbought nor oversold. The STOCH value of 87.14 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MKKGY.
Merck KGaA Sponsored ADR Peers Comparison
Overall Rating
- MKKGY72Outperform
RDY67Neutral
TAK67Neutral
TEVA65Neutral
VTRS63Neutral
HLN62Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| MKKGY | 72Outperform | $73.47B | 27.76 | 8.08% | 1.52% | 6.81% | -11.14% |
| RDY | 67Neutral | $11.86B | 40.24 | 7.37% | 0.59% | -10.52% | -55.45% |
| TAK | 67Neutral | $67.25B | 27.16 | 5.07% | 3.37% | 0.67% | -12.01% |
| TEVA | 65Neutral | $47.43B | 70.17 | 9.18% | ― | 4.40% | ― |
| VTRS | 63Neutral | $21.86B | -52.88 | -2.79% | 2.52% | 4.92% | 87.81% |
| HLN | 62Neutral | $37.61B | 17.61 | 9.89% | 1.43% | 4.99% | 12.37% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MKKGY | Merck KGaA Sponsored ADR | 33.78 | 8.37 | 32.93% | |
| RDY | Dr. Reddy's Laboratories Ltd | 14.17 | 0.83 | 6.25% | |
| VTRS | Viatris, Inc. | 19.04 | 8.87 | 87.19% | |
| TEVA | Teva Pharmaceutical Industries Limited | 42.09 | 23.59 | 127.51% | |
| TAK | Takeda Pharmaceutical Company | 20.91 | 7.49 | 55.81% | |
| HLN | Haleon PLC Sponsored ADR | 8.66 | -0.54 | -5.91% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 19, 2026